tbuckley/cabot-search huggingface dataset:
Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.
Authors: Daniel A. Goldstein, Qiushi Chen, Turgay Ayer, Kelvin K. Chan, Kiran Virik, Ariel Hammerman, Baruch Brenner, Christopher Flowers, Peter Hall
Journal: Journal of Clinical Oncology (2016)

6518 Background: In the United States, the addition of bev to 1st-line chemotherapy in mCRC provides an additional 0.10 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio (ICER) of $571,240/QALY (Goldstein et al. Journal of Clinical Oncology, 2015). However, this estimate of value is not transferrable between countries due to variable international pricing strategies. Our objective was to establish the cost-effectiveness of bev in mCRC in 5 different countries: the US, the UK, Canada (CAN), Australia (AUS), and Israel (ISR). Methods: We performed the analysis on the basis of a previously published Markov model (Goldstein et al. JCO, 2015). Input data for efficacy, adverse events and quality of life were considered to be standard for all countries. We used country specific prices for all healthcare services, medications, and administration costs. For the UK, all costs were obtained from UK Department of Health, National Health Service and British National Formulary. For CAN, all costs were obtained from the Ontario Drug Benefit formulary, Ontario Schedule of Benefits, and Sunnybrook Pharmacy Stores Department. For AUS, all costs were obtained from the Pharmaceutical Benefits Scheme and the Australian Medicare Benefits Schedule. For ISR, all costs were obtained from the Israeli Ministry for Health and Clalit Health Services. All costs were converted from local currency to US dollars in December 2015. Probabilistic sensitivity analyses (PSA) assessed the model robustness against the parameter uncertainties. Results: Base case results are displayed in the table. PSA demonstrated 0% likelihood of bev being cost cost-effective in any country at a willingness to pay threshold of $150,000 per QALY. Conclusions: Although there are differences in the value of bev between countries, the addition of bev to first-line chemotherapy for mCRC is not cost-effective across all 5 countries analyzed. This study provides a novel framework for analyzing the value of a cancer drug with a single model from the perspectives of multiple international payers. USA UK Canada Australia Israel Total incremental cost (2015 US$) 60,551 33,253 35,698 29,512 37,995 ICER (US$/QALY) 571,240 313,704 336,778 278,417 358,445
MitoFish and MiFish Pipeline: A Mitochondrial Genome Database of Fish with an Analysis Pipeline for Environmental DNA Metabarcoding
Authors: Yukuto Sato, Masaki Miya, Tsukasa Fukunaga, Tetsuya Sado, Wataru Iwasaki
Journal: Molecular Biology and Evolution (2018)

Fish mitochondrial genome (mitogenome) data form a fundamental basis for revealing vertebrate evolution and hydrosphere ecology. Here, we report recent functional updates of MitoFish, which is a database of fish mitogenomes with a precise annotation pipeline MitoAnnotator. Most importantly, we describe implementation of MiFish pipeline for metabarcoding analysis of fish mitochondrial environmental DNA, which is a fast-emerging and powerful technology in fish studies. MitoFish, MitoAnnotator, and MiFish pipeline constitute a key platform for studies of fish evolution, ecology, and conservation, and are freely available at http://mitofish.aori.u-tokyo.ac.jp/ (last accessed April 7th, 2018).
Surface impact on nanoparticle-based magnetic resonance imaging contrast agents
Authors: Weizhong Zhang, Lin Liu, Hongmin Chen, Kai Hu, Ian Delahunty, Shi Gao, Jin Xie
Journal: Theranostics (2018)

Magnetic resonance imaging (MRI) is one of the most widely used diagnostic tools in the clinic.To improve imaging quality, MRI contrast agents, which can modulate local T1 and T2 relaxation times, are often injected prior to or during MRI scans.However, clinically used contrast agents, including Gd 3+ -based chelates and iron oxide nanoparticles (IONPs), afford mediocre contrast abilities.To address this issue, there has been extensive research on developing alternative MRI contrast agents with superior r1 and r2 relaxivities.These efforts are facilitated by the fast progress in nanotechnology, which allows for preparation of magnetic nanoparticles (NPs) with varied size, shape, crystallinity, and composition.Studies suggest that surface coatings can also largely affect T1 and T2 relaxations and can be tailored in favor of a high r1 or r2.However, the surface impact of NPs has been less emphasized.Herein, we review recent progress on developing NP-based T1 and T2 contrast agents, with a focus on the surface impact.
Identifying Vulnerable Periods of Neurotoxicity to Triclosan Exposure in Children
Authors: Medina S. Jackson-Browne, George D. Papandonatos, Aimin Chen, Antonia M. Calafat, Kimberly Yolton, Bruce P. Lanphear, Joseph M. Braun
Journal: Environmental Health Perspectives (2018)

Background: Exposure to triclosan, an endocrine disrupting chemical, may affect thyroid hormone homeostasis and adversely affect neurodevelopment. Objective: Using a longitudinal pregnancy and birth cohort, we investigated associations between triclosan exposures during different time windows, and cognitive test scores at 8 y of age in 198 children from the HOME Study. Methods: We quantified triclosan in urine samples from mother–child pairs up to nine times between the second trimester of gestation and 8 y of age. The Wechsler Intelligence Scale for Children-IV [i.e., Full-Scale Intelligence Quotient (IQ)] assessment was administered to HOME Study children at 8 y of age. We estimated covariate-adjusted triclosan–IQ associations at each visit. We also tested whether associations between triclosan concentrations and cognitive test scores varied among exposure at different time periods. Results: Full-Scale IQ was not significantly associated with urinary triclosan concentrations during gestation or childhood but was significantly associated with a 10-fold increase in maternal urinary triclosan concentration at delivery [−4.5 points (95% CI: −7.0, −2.0)]. Perceptual Reasoning Index (PRI) scores were significantly decreased in association with urinary triclosan concentrations at delivery and at 2 y of age. Associations between repeated triclosan concentrations and cognitive test scores significantly varied among exposure at different time periods for Full-Scale IQ, PRI, Verbal Comprehension Index, and Working Memory (triclosan–visit interaction p≤0.04). Conclusion: Urinary triclosan concentrations at delivery, but not during mid to late pregnancy and childhood, were associated with significantly lower children's cognitive test scores at 8 y of age in this cohort of U.S. children. https://doi.org/10.1289/EHP2777
P350Deficiency in endothelial cell tetrahydrobiopterin increases resistance vascular remodelling, blood pressure, and susceptibility to aortic abdominal aneurysm in response to angiotensin II
Authors: S Chuaiphichai, V S Rashbrook, A B Hale, L Trelfa, E Mcneill, C A Lygate, K M Channon, G Douglas
Journal: Cardiovascular Research (2018)
Prevalence and clinic impact of rectal colonization by multidrug-resistant bacteria in descompensated cirrhosis
Authors: M. Hernandez-Tejero, F.M. Reverte, F. Aziz, C. Pitart, I. Campo, A. Carpio, E. Reverter, A. Escorsell, P. Ginès, A. Soriano, J. Vila, J. Fernandez
Journal: Journal of Hepatology (2018)
<i>Vital Signs</i>: Trends in Reported Vectorborne Disease Cases — United States and Territories, 2004–2016
Authors: Ronald Rosenberg, Nicole P. Lindsey, Marc Fischer, Christopher J. Gregory, Alison F. Hinckley, Paul S. Mead, Gabriela Paz-Bailey, Stephen H. Waterman, Naomi A. Drexler, Gilbert J. Kersh, Holley Hooks, Susanna K. Partridge, Susanna N. Visser, Charles B. Beard, Lyle R. Petersen
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Vectorborne diseases are major causes of death and illness worldwide. In the United States, the most common vectorborne pathogens are transmitted by ticks or mosquitoes, including those causing Lyme disease; Rocky Mountain spotted fever; and West Nile, dengue, and Zika virus diseases. This report examines trends in occurrence of nationally reportable vectorborne diseases during 2004-2016.Data reported to the National Notifiable Diseases Surveillance System for 16 notifiable vectorborne diseases during 2004-2016 were analyzed; findings were tabulated by disease, vector type, location, and year.A total 642,602 cases were reported. The number of annual reports of tickborne bacterial and protozoan diseases more than doubled during this period, from >22,000 in 2004 to >48,000 in 2016. Lyme disease accounted for 82% of all tickborne disease reports during 2004-2016. The occurrence of mosquitoborne diseases was marked by virus epidemics. Transmission in Puerto Rico, the U.S. Virgin Islands, and American Samoa accounted for most reports of dengue, chikungunya, and Zika virus diseases; West Nile virus was endemic, and periodically epidemic, in the continental United States.Vectorborne diseases are a large and growing public health problem in the United States, characterized by geographic specificity and frequent pathogen emergence and introduction. Differences in distribution and transmission dynamics of tickborne and mosquitoborne diseases are often rooted in biologic differences of the vectors. To effectively reduce transmission and respond to outbreaks will require major national improvement of surveillance, diagnostics, reporting, and vector control, as well as new tools, including vaccines.
Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.
Authors: Ian Edward Smith, Dianne M Finkelstein, Joyce O'Shaughnessy, Beverly Moy, Bent Ejlertsen, Manfred Kaufmann, Aman Buzdar, Pierre Fumoleau, William John Gradishar, Miguel Martin, Frances Boyle, Martine J. Piccart-Gebhart, Kathleen I. Pritchard, Deborah Lindquist, Erica Rappold, Lisa Simone Williams, Pedro E.R. Liedke, Yanin Chavarri-Guerra, Paul Edward Goss
Journal: Journal of Clinical Oncology (2012)

596 Background: TEACH is a randomized, double-blind, placebo (P)-controlled trial evaluating lapatinib (L) in reducing relapse risk in trastuzumab -naive patients (pts) previously treated with chemotherapy for HER2+ BC. The primary results (presented at SABCS 2011) showed a hazard ratio (HR) for disease-free survival (DFS) in L arm compared with P of 0.83 (95% confidence interval [CI] 0.70-1.00; stratified log-rank 2-sided P=.053). The predefined hormone receptor negative subgroup was analyzed, which in contrast to the hormone receptor positive subgroup of the ITT population (N=3147) had a significantly improved DFS. Methods: 3161 HER2+ BC pts (Stage I-IIIc) were randomized 1:1 to L daily or P for 1 year (yr). Primary endpoint was DFS in the ITT population. Central nervous system (CNS) recurrence rate was a secondary endpoint. A subgroup analysis by Cox Proportional Hazards Regression Models was performed for the hormone receptor negative pts from the ITT population. Results: 1288 pts (41%) comprised the hormone receptor negative subgroup of the ITT (L:639, and P:649). Median time from diagnosis to randomization was 2.4 (0.3-15) yrs, median follow-up was 4 yrs. Median age for this subgroup was 53 (24-87) yrs. With 85 events in L arm and 128 in P arm, the HR for DFS for hormone receptor negative pts was 0.68 (95%CI 0.52-0.89) favoring L. Most hormone receptor negative subgroups showed benefit for L: pts up to 1 yr from diagnosis (HR 0.64; 95%CI 0.41-0.99), node negative (HR 0.57; 95%CI 0.35-0.92), premenopausal (HR 0.59, 95%CI 0.37-0.94), and those who received prior anthracycline chemotherapy without taxanes (HR 0.63; 95%CI 0.43-0.92). Node positive patients had a trend to benefit from L (HR 0.74; 95%CI 0.53-1.03). CNS as one site of initial recurrence occurred in 1% in L (n=7) and P (n=8) arms. Conclusions: Lapatinib improved DFS in patients early or late in follow-up from diagnosis of HER2+, hormone receptor negative BC. Similar subset analyses are important in other large adjuvant anti-HER2 therapy trials. Results might provide a better understanding of the subtypes of HER2+ disease and help to further individualized therapy.
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy
Authors: So-Yon Lim, Christa E. Osuna, Peter T. Hraber, Joe Hesselgesser, Jeffrey M. Gerold, Tiffany L. Barnes, Srisowmya Sanisetty, Michael S. Seaman, Mark G. Lewis, Romas Geleziunas, Michael D. Miller, Tomas Cihlar, William A. Lee, Alison L. Hill, James B. Whitney
Journal: Science Translational Medicine (2018)

SIV-infected rhesus macaques on antiretroviral therapy experienced a reduction in the SIV reservoir after treatment with TLR7 agonists.
2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging—Best Practices for Safety and Effectiveness, Part 2: Radiological Equipment Operation, Dose-Sparing Methodologies, Patient and Medical Personnel Protection
Authors: John W. Hirshfeld, Victor A. Ferrari, Frank M. Bengel, Lisa Bergersen, Charles E. Chambers, Andrew J. Einstein, Mark J. Eisenberg, Mark A. Fogel, Thomas C. Gerber, David E. Haines, Warren K. Laskey, Marian C. Limacher, Kenneth J. Nichols, Daniel A. Pryma, Gilbert L. Raff, Geoffrey D. Rubin, Donnette Smith, Arthur E. Stillman, Suma A. Thomas, Thomas T. Tsai, Louis K. Wagner, L. Samuel Wann
Journal: Journal of the American College of Cardiology (2018)
Abstract 23085: 30-Day Outcomes of Transseptal Transcatheter Mitral Valve Replacement for Failed Surgical Bioprostheses (Mitral Valve-in-Valve): The MITRAL Trial (Mitral Implantation of TRAnscatheter vaLves)
Authors: Mayra Guerrero, Amit Pursnani, Michael Salinger, Dee Dee Wang, Susheel Kodali, Isaac George, Rebecca T Hahn, Lowell Satler, Ignacio Inglessis, Mackram Eleid, Christopher Meduri, Vivek Rajagopal, Mark Reisman, Gabriel Aldea, Marvin Eng, Ron Waksman, Augusto Pichard, Igor Palacios, Hyde M Russell, Jorge Saucedo, Saibal Kar, Raj Makkar, William O'Neill, Charanjit Rihal, Martin Leon, Ted Feldman
Journal: Circulation (2017)

Introduction: Transcatheter mitral valve replacement (TMVR) using aortic transcatheter heart valves (THV) is developing as an alternative to surgery for patients with severely degenerated mitral valve (MV) bioprostheses. Retrospective self-reported registries have collected outcomes on these TMVR procedures in the STS/ACC Transcatheter Valve Therapy Registry and in the Valve-in-Valve International Database. Most reported TMVR procedures for failed surgical bioprostheses have been performed using a transapical access approach. A prospective comprehensive evaluation of mitral Valve-in-Valve (VIV) outcomes, including transseptal access has not previously been conducted. Objectives: To evaluate in-hospital and 30-day clinical outcomes of transseptal mitral VIV with SAPIEN 3 THV in patients with very high surgical risk. Methods: Prospective enrollment of very high surgical risk patients with symptomatic severely degenerated MV surgical bioprostheses in 30 patients at 15 sites in the U.S. Candidates were assessed by a case review committee prior to approval. Baseline qualifying echocardiograms and cardiac CT studies were analyzed by independent core labs. Echocardiograms, cardiac CT studies and neurology evaluations were also performed after mitral VIV procedures. Clinical events were adjudicated by a clinical events committee and safety was monitored by a data safety monitoring board. Results: 26 patients have been enrolled between July 2016 and June 2017. Mean age was 83 years, 62% female, mean STS score was 10% and 62% were in New York Heart Association class III or IV. Transseptal access was used in all procedures. Technical success was achieved in all patients and there was no in-hospital mortality. There was no 30-day cardiovascular mortality and 4% (1 patient) 30-day all-cause mortality (1 patient died of asphyxia on day 29 after choking on pills at home), which was lower than the 30-day mortality in the TVT registry (9%). Detailed procedural, in-hospital and 30-day outcomes will be presented on the complete cohort of 30 patients. Conclusions: In patients without surgical alternatives, transseptal mitral ViV procedures in failed surgical bioprostheses are associated with high technical and procedural success and low 30-day mortality.
Temozolomide for immunomodulation in the treatment of glioblastoma
Authors: Aida Karachi, Farhad Dastmalchi, Duane A Mitchell, Maryam Rahman
Journal: Neuro-Oncology (2018)

Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy. Due to the limited efficacy of existing therapies, immunotherapy is being widely investigated for patients with GBM. However, initial immunotherapy trials in GBM patients have had disappointing results as monotherapy. Therefore, combinatorial treatment strategies are being investigated. Temozolomide has several effects on the immune system that are dependent on mode of delivery and the dosing strategy, which may have unpredicted effects on immunotherapy. Here we summarize the immune modulating role of temozolomide alone and in combination with immunotherapies such as dendritic cell vaccines, T-cell therapy, and immune checkpoint inhibitors for patients with GBM.
High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study
Authors: A. Abergel, C. Hezode, T. Asselah, D. Larrey, J. Gournay, V. Loustaud-Ratti, V.D. Martino, I.F. Hubert, D. Samuel, B. Chanteranne, M. Dodel, F. Faure, B. Pereira, G. Lamblin, C. Campos, L. Muti, M. Reymond, C. Teilhet
Journal: Journal of Hepatology (2018)
Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study
Authors: C. Schramm, G. Hirschfield, A.L. Mason, H. Wedemeyer, L. Klickstein, S. Neelakantham, P. Koo, J. Sanni, M. Badman, D. Jones
Journal: Journal of Hepatology (2018)
Relative adrenal insufficiency in acute-on chronic liver failure – a new futility marker?
Authors: S. Chiriac, A. Trifan, A.-M. Singeap, C. Cojocariu, I. Girleanu, O. Stoica, T. Cuciureanu, L. Huiban, C.-M. Muzica, C. Alexandru, C. Stanciu
Journal: Journal of Hepatology (2018)
Histopathologic assessment of fatty liver progression in a rodent model of chronic intake of high-fat diet, ethanol or both
Authors: A.R. Mendoza, A. Campos-Espinosa, M. Galicia-Moreno, B. León-Mancilla, T.A. Arévalo-Sánchez, K.Z.M. Ávila, I.I. Romero-Bello, R.O. Dorothy, A. Pérez-Torres, C. Guzman, G. Gutierrez-Reyes
Journal: Journal of Hepatology (2018)
Suicidal Ideation and Attempts Among Students in Grades 8, 10, and 12 — Utah, 2015
Authors: Marissa L. Zwald, Francis B. Annor, Amanda Wilkinson, Mike Friedrichs, Anna Fondario, Angela C. Dunn, Allyn Nakashima, Leah K. Gilbert, Asha Ivey-Stephenson
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Suicidal thoughts and behaviors among youths are important public health concerns in Utah, where the suicide rate among youths consistently exceeds the national rate and has been increasing for nearly a decade (1). In March 2017, CDC was invited to assist the Utah Department of Health (UDOH) with an investigation to characterize the epidemiology of fatal and nonfatal suicidal behaviors and identify risk and protective factors associated with these behaviors, among youths aged 10-17 years. This report presents findings related to nonfatal suicidal behaviors among Utah youths. To examine the prevalence of suicidal ideation and attempts among Utah youths and evaluate risk and protective factors, data from the 2015 Utah Prevention Needs Assessment survey were analyzed. Among 27,329 respondents in grades 8, 10, and 12, 19.6% reported suicidal ideation and 8.2% reported suicide attempts in the preceding 12 months. Significant risk factors for suicidal ideation and attempts included being bullied, illegal substance or tobacco use in the previous month, and psychological distress. A significant protective factor for suicidal ideation and attempts was a supportive family environment. UDOH, local health departments, and other stakeholders are using these findings to develop tailored suicide prevention strategies that address multiple risk and protective factors for suicidal ideation and attempts. Resources such as CDC's Preventing Suicide: A Technical Package of Policy, Programs, and Practices (2) can help states and communities identify strategies and approaches using the best available evidence to prevent suicide, which include tailored strategies for youths.
Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis
Authors: Jiraporn Jitprapaikulsan, A. Sebastian Lopez Chiriboga, Eoin P. Flanagan, James P. Fryer, Andrew McKeon, Brian G. Weinshenker, Sean J. Pittock
Journal: JAMA Neurology (2018)

This cohort study presents serological data with regard to 2 novel glial targets (myelin oligodendrocyte glycoprotein and glial fibrillary acidic protein) in recurrent longitudinally extensive transverse myelitis.
Machine learning approaches for non-invasive ultrasound. Based quantitative assessment of liver steatosis
Authors: N.D. Lascio, C. Avigo, A. Salvati, N. Martini, M. Ragucci, S. Monti, A. Prinster, D. Chiappino, M. Mancini, F. Bonino, M. Brunetto, F. Faita
Journal: Journal of Hepatology (2018)
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity
Authors: Christian Büll, Thomas J. Boltje, Natasja Balneger, Sarah M. Weischer, Melissa Wassink, Jasper J. van Gemst, Victor R. Bloemendal, Louis Boon, Johan van der Vlag, Torben Heise, Martijn H. den Brok, Gosse J. Adema
Journal: Cancer Research (2018)

Abstract Sialic acid sugars on the surface of cancer cells have emerged as potent immune modulators that contribute to the immunosuppressive microenvironment and tumor immune evasion. However, the mechanisms by which these sugars modulate antitumor immunity as well as therapeutic strategies directed against them are limited. Here we report that intratumoral injections with a sialic acid mimetic Ac53FaxNeu5Ac block tumor sialic acid expression in vivo and suppress tumor growth in multiple tumor models. Sialic acid blockade had a major impact on the immune cell composition of the tumor, enhancing tumor-infiltrating natural killer cell and CD8+ T-cell numbers while reducing regulatory T-cell and myeloid regulatory cell numbers. Sialic acid blockade enhanced cytotoxic CD8+ T-cell–mediated killing of tumor cells in part by facilitating antigen-specific T-cell–tumor cell clustering. Sialic acid blockade also synergized with adoptive transfer of tumor-specific CD8+ T cells in vivo and enhanced CpG immune adjuvant therapy by increasing dendritic cell activation and subsequent CD8+ T-cell responses. Collectively, these data emphasize the crucial role of sialic acids in tumor immune evasion and provide proof of concept that sialic acid blockade creates an immune-permissive tumor microenvironment for CD8+ T-cell–mediated tumor immunity, either as single treatment or in combination with other immune-based intervention strategies. Significance: Sialic acid sugars function as important modulators of the immunosuppressive tumor microenvironment that limit potent antitumor immunity. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/13/3574/F1.large.jpg. Cancer Res; 78(13); 3574–88. ©2018 AACR.
Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C
Authors: Stephen Bloom, William Kemp, Amanda Nicoll, Stuart K. Roberts, Paul Gow, Anouk Dev, Sally Bell, Siddharth Sood, Ian Kronborg, Virginia Knight, Diana Lewis, John Lubel
Journal: Journal of Hepatology (2018)